UCB Positive Data for Epileptic Encephalopathy Drug

UCB is announcing positive data from a Phase 3 clinical trial evaluating fenfluramine as an adjunctive treatment for CDKL5 Deficiency Disorder (CDD). The trial met both its primary and key secondary endpoints in patients with the rare and severe form of epilepsy, according to the company.

The primary outcome was based on the median percent change in countable motor seizure frequency from baseline. According to UCB, the results demonstrated a statistically significant reduction in seizures for those receiving fenfluramine compared to placebo. Full data will be presented at an upcoming scientific meeting.

UCB says CDD is an ultra-rare developmental and epileptic encephalopathy caused by mutations in the CDKL5 gene located on the X chromosome. Fenfluramine is currently approved for treating seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients aged two years and older, according to the company.